Catalyst Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Catalyst Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CPRX

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. 

CEO
Richard John Daly
CEORichard John Daly
Employees
182
Employees182
Headquarters
Coral Gables, Florida
HeadquartersCoral Gables, Florida
Founded
2002
Founded2002
Employees
182
Employees182

CPRX Key Statistics

Market cap
3.81B
Market cap3.81B
Price-Earnings ratio
17.90
Price-Earnings ratio17.90
Dividend yield
Dividend yield
Average volume
3.71M
Average volume3.71M
High today
$31.19
High today$31.19
Low today
$31.05
Low today$31.05
Open price
$31.17
Open price$31.17
Volume
2.87M
Volume2.87M
52 Week high
$32.56
52 Week high$32.56
52 Week low
$19.05
52 Week low$19.05

Stock Snapshot

As of today, Catalyst Pharmaceuticals(CPRX) shares are valued at $31.05. The company's market cap stands at 3.81B, with a P/E ratio of 17.90.

On 2026-05-13, Catalyst Pharmaceuticals(CPRX) stock moved within a range of $31.05 to $31.19. With shares now at $31.05, the stock is trading 0.0% above its intraday low and -0.4% below the session's peak.

Trading activity shows a volume of 2.87M, compared to an average daily volume of 3.71M.

Over the past 52 weeks, Catalyst Pharmaceuticals(CPRX) stock has traded between a high of $32.56 and a low of $19.05.

Over the past 52 weeks, Catalyst Pharmaceuticals(CPRX) stock has traded between a high of $32.56 and a low of $19.05.

CPRX News

TipRanks 2d
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 4d
Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid

Catalyst Pharmaceuticals (NasdaqCM:CPRX) has settled all pending FIRDAPSE patent litigation with Hetero Labs. The agreement prevents Hetero from launching a ge...

Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid
Benzinga 6d
Family-Run Angelini Pharma Buys Catalyst Pharmaceuticals For Over 4 Billion

The boards of Angelini Pharma and Catalyst unanimously approved the deal. Angelini Group is a family-run company chaired by Thea Paola Angelini, a fourth-gener...

Family-Run Angelini Pharma Buys Catalyst Pharmaceuticals For Over 4 Billion

Analyst ratings

67%

of 6 ratings
Buy
33.3%
Hold
66.7%
Sell
0%

People also own

Based on the portfolios of people who own CPRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.